text:
ADVISORY BOARDadminpmls20162022-12-19T08:17:47-05:00
As Precision Medicine has changed over the past several years, we have been diligent in ensuring that the composition of our Editorial Advisory Board reflects those changes. Our EAB represents how precision medicine has come to expand beyond cancer and sequencing to embrace other therapeutic areas and analytical domains. In addition to these areas, we also saw the need to draw from various organizations and institutions – therapeutic to diagnostic to analytical to academic. In light of these changes, the EAB now encompasses the range of scientific, technical, and medical disciplines in precision medicine. Experts have been added to keep pace with emerging capabilities, such as machine learning, artificial intelligence, and advanced computational methods. We look to our EAB for deep advice on topics and directions, using their input to shape content for you, the audience of the Journal and the Summits.
And, of course, we express our profound gratitude to them for their contribution and look to them for their ongoing support. Thank you!
Howard McLeod, PharmD, FASCO, FCCP
Medical Director, Precision Medicine, Geriatric Oncology Consortium; Professor, University of South Florida, College of Pharmacy
Dr Howard McLeod is an internationally recognized expert in precision medicine, having made novel contributions at the discovery, translation, implementation, and policy levels. He is the Medical Director for Precision Medicine at the Geriatric Oncology Consortium and a Professor at the University of South Florida Taneja College of Pharmacy. Dr McLeod chaired the NHGRI eMERGE network external scientific panel for the past decade and was a recent member of both the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. Dr McLeod has been recognized as a Fellow of both the American Society of Clinical Oncology and the American College of Clinical Pharmacy and was recently ranked #1 USA/#2 World for Pharmacogenomics. He has also been an active Board Member and/or Founder for over a dozen privately held and publicly traded companies. Howard has published over 575 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance innovative healthcare.
Robert C. Green, MD, MPH
Professor of Medicine; Director, G2P Research Program; Associate Director for Research, Partners Personalized Medicine, Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Broad Institute and Harvard Medical School
Robert C. Green, MD, MPH is a medical geneticist and physician-scientist who directs the G2P Research Program in translational genomics and health outcomes in the Division of Genetics at Brigham and Women's Hospital and Harvard Medical School.
Dr. Green is principal investigator of the NIH-funded REVEAL Study, in which a cross-disciplinary team has conducted 4 separate multi-center randomized clinical trials since 2000, collectively enrolling 1100 individuals in order to explore emerging themes in translational genomics. Dr. Green also co-directs the NIH-funded PGen Study, one of the first prospective studies of direct-to-consumer genetic testing services. He is principal investigator of the MedSeq Project, the first NIH-funded randomized trial to explore the use of whole genome sequencing in the clinical practice of medicine and co-directs the BabySeq Project, the first NIH-funded trial of sequencing in newborns. The MedSeq and BabySeq Projects apply genome sequencing both in patients who are affected with hereditary disease and in those who are healthy, in order to study downstream impact on health, behavior and health care costs.
Dr. Green is currently Associate Director for Research of the Partners Center for Personalized Genetic Medicine, a Board Member of the Council for Responsible Genetics and a member of the Informed Cohort Oversight Boards for both the Children's Hospital Boston Gene Partnership Program and the Coriell Personalized Medicine Collaborative. He was the lead author of the recently published recommendations from the American College of Medical Genetics and Genomics for management of incidental findings in clinical sequencing.
Alessandra Cesano, MD, PhD
Chief Medical Officer, ESSA
Alessandra Cesano, MD, PhD is Chief Medical Officer at ESSA. Prior to joining ESSA, Dr. Cesano was the Chief Medical Officer of NanoString Inc from July 2015 until June 2019 where she focused in the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance.
Prior to joining NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R and D group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals.
Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania.
Howard A. "Skip" Burris III, MD, FASCO, FACP
Chief Medical Officer, Sarah Cannon, Executive Director, Drug Development, Sarah Cannon Research Institute
Howard A. "Skip" Burris III, MD, FASCO, FACP serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for Sarah Cannon Research Institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.
Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first–in–human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved. In 1997, he established in Nashville the first community–based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts.
Dr. Burris served as president of ASCO in 2019-2020 and is serving as Chair of the Board for the 2020-2021 term. He also currently serves on the Board of ASCO's Conquer Cancer Foundation. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.
Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.
Christina Waters, PhD, MBA
Chief Executive Officer and Founder, RARE Science
Christina Waters has been responsible for leading medical research in a broad range of organizations ranging from academia and disease – focused non-profits to biotech and large pharmaceutical companies. Her broad range of experience in basic, translational, and clinical research and business strategies converge to specialize in the development of new approaches to personalized medicine and health, creation of synergistic partnerships and implementation of new innovative research initiatives.
She is CEO and Founder of RARE Science, a non-profit research organization that enables the rare scientific research community to accelerate discovery of therapeutic solutions for patients with rare disease. In addition, she serves as a Scientific Advisory board member, for Global Genes|Rare Project, which focuses on advocacy and education for the rare disease community and as a Senior Advisor for Personalized Medicine and Health Informatics for Pricewaterhouse Coopers' Personalized Medicine and Health Sciences Practices serving academic and research organizations across the healthcare continuum.
Dr. Waters received her Ph.D. in Genetics from the University of California, Davis as a NIH Biotechnology Fellow. She was a Postdoctoral Scholar and Associate of the Howard Hughes Medical Institute in the Division of Biology, California Institute of Technology. Dr. Waters also completed an NIH Postdoctoral fellowship at University of California, Berkeley, and received a Bachelor of Science in Biology from San Diego State University. Dr. Waters received her MBA from University of California, Los Angeles.
Hannah Mamuszka
Chief Executive Officer & Founder, Alva10
Hannah Mamuszka is the Founder and CEO of Alva10, which focuses on bringing diagnostics to the forefront of Precision Medicine by partnering with payers and employers with diagnostic developers to create a new value-based healthcare model that pulls diagnostics into the market. Ms Mamuszka has spent more than 20 years in biotech and diagnostics, with extensive experience in both drug and diagnostic development, validation, and commercialization. Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She is a Board Director at Bionano Genomics (BNGO), regularly speaks on issues regarding advancement of technology in healthcare, and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Kristine Ashcraft, MBA
Head of Pharmacogenomics, Invitae
Kristine Ashcraft is a molecular biologist by training and the Head of Pharmacogenomics at Invitae. Ms. Ashcraft was the Chief Executive Officer of Youscript, Inc. during its acquisition by Invitae. She has worked in precision medicine since 2000 and was recently named one of the 25 Leading Global Voices in the space. Ms. Ashcraft has authored multiple publications on the clinical and economic benefits of pharmacogenomic testing including one lauded as one of the most influential publications at a recent AMIA meeting. She has been interviewed by numerous media outlets including the New York Times, the Wall Street Journal, and NBC Nightly News and has spoken at numerous Precision Medicine Conferences. She is committed to being a catalyst in the adoption of precision medicine.
Sarah Hersey, MBA, MS
Vice President, Precision Medicine, Bristol Myers Squibb
Sarah is currently the Vice President, of Precision Medicine for Bristol Myers Squibb. She has more than 20 years of industry experience in leading R&D organizations, CLIA and GLP laboratories, device manufacturing, consortiums, assessment and implementation of technology strategies, and development of in vitro diagnostics. In addition, she continuously works to further education and awareness in the Precision Medicine and Companion Diagnostic spaces. Prior to joining BMS, Sarah was the Vice President, Precision Medicine & Companion Diagnostics for Celgene, where she founded their Precision Medicine Organization in 2016. She joined Celgene after having held the position as the Global Head of Future Precision Medicine for Novartis, where the team submitted and gained approval for multiple Health Authority applications; including the first pre-market approval for a distributable NGS CDx.
Sarah has also held multiple roles with increasing responsibility within Johnson and Johnson (JNJ) including Global Head of Operations, Assay Program Leader for Companion Diagnostics Center of Excellence, Director of Materials Process Development and Enabling Technologies. At JNJ, Sarah co-led or was the operating company's representative on key corporate strategic initiatives including, but not limited to: Nanotechnology, Critical to Quality Flow Down and Pathology Business Opportunity Team and had accountability for CLIA laboratories in the US and Europe. In addition, her prior experience also includes start-up and establishment of a GLP laboratory, technical support and quality assurance. Sarah has BS and MS degrees in Chemistry and Biology from Northern Illinois University, Regulatory Affairs Certification (RAC) and an MBA from California State University.
Jeanette McCarthy, PhD, MPH
Founder, Precision Medicine Advisors; Adjunct Associate Professor, Community and Family Medicine, Duke University Adjunct Associate Professor, Department of Medicine, UCSF
Jeanette McCarthy is a UC Berkeley trained genetic epidemiologist and spent the early part of her career in industry at Millennium Pharmaceuticals before transitioning to academia. She currently holds adjunct faculty positions at Duke University and UCSF. Her previous research had focused on the genetic underpinnings of complex diseases, both infectious and chronic. More recently, she has become a leading educator in the field of genomic and precision medicine involved in demystifying genomics for non-technical audiences, including health care providers, patients and other stakeholders. In 2014 she helped launch the first consumer-facing magazine in this field, Genome, where she served as editor-in-chief until 2016. She teaches genomic and precision medicine through UCSF and UC Berkeley Extension and online through Coursera and through the Precision Medicine Academy (precisionmedicineacademy.org). She also designs and delivers custom workshops and courses to international audiences through her consulting business (precisionmedicineadvisors.com). Jeanette is coauthor of the new book, Precision Medicine: A Guide to Genomics in Clinical Practice (2016, McGraw Hill Education).
John Quackenbush, PhD
Henry Pickering Walcott Professor of Computational Biology and Bioinformatics Chair, Department of Biostatistics, Harvard University T.H. Chan School of Public Health
John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health and Professor of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute.
John's PhD was in Theoretical Physics, in 1992 he received a fellowship from the National Institutes of Health to work on the Human Genome Project, which led him from the Salk Institute to Stanford University to The Institute for Genomic Research (TIGR) before moving to Harvard in 2005. John's research uses massive data from DNA sequencing and other assays to model functional networks in human cells. By comparing networks between groups of individuals, he has found new drug targets, explored chemotherapy resistance, and investigated differences between the sexes. He has made pioneering discoveries about how the genetic variants work together to determine our traits.
John has published more than 280 papers; his work has been cited more than 65,000 times. He has received numerous awards for his work, including recognition in 2013 as a White House Open Science Champion of Change. He is also the co-founder of Genospace, a precision medicine software company that was purchased by the Hospital Corporation of America in 2017.
Dr. George Poste, CBE, FRS, DVM, PhD
Del E. Webb Professor, Health Innovation; Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University
Dr. George Poste is the Del E. Webb Professor of Health Innovation and Chief Scientist at The Complex Adaptive Systems Initiative (CASI) at Arizona State University (ASU) (http://www.casi.asu.edu). This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision medicine and the remote monitoring of health status using miniaturized body sensors and mobile devices. He assumed this post in 2009. From 2003 to 2009 he directed and built The Biodesign Institute at ASU (https://biodesign.asu.edu/).
As of January 2021, Dr. Poste assumed additional leadership of the new Institute for Future Health (IFH) a joint venture between ASU and the University of Arizona in precision health and digital health. This focuses on remote health monitoring technologies with a focus on the use of digital psychiatry and cognitive computing to address the growing burden of mental illness.
He has published more than 400 research papers and edited 14 books on pharmaceutical technologies, cancer and infectious diseases. He has received honorary degrees in science, law and medicine and was awarded the rank of Commander of the British Empire by Queen Elizabeth II for his contributions to research and international security.
He currently serves on the Board of Directors of Exelixis, Caris Life Sciences, MediSix (Singapore) and the Scientific Advisory Boards of the A. Alfred Taubman Medical Research Institute at the University of Michigan, Synthetic Genomics, Vir Biotechnology, iNanoBio and Haplogen GmbH (Vienna).
From 1992 to 1999, he was Chief Science and Technology Officer and President, R&D, of SmithKline Beecham (SB) (now GlaxoSmithKilne). During his tenure at SB, he was associated with the successful registration of multiple drug, vaccine and diagnostic products. He has served on the Board of Directors of Illumina, Structural Genomix (acquired by Lilly), Orchid Biosciences (acquired by LapCorp), diaDexus (acquired by Vaxgen), Monsanto (acquired by Bayer) and Advanced PCS (acquired by CVS-Caremark).
In 2004 he was named "R&D Scientist of the Year" by R&D Magazine, he received the Einstein award from the Global Business Leadership Council (2006), the Scrip Lifetime Achievement award voted by the leadership of the global pharmaceutical industry (2009) and the Arizona Bioindustry Association Pioneer Award (2016).
He is a Fellow of the U.K. Royal Society, the Royal College of Pathologists, the U.K. Academy of Medicine and The American Institute for Medical and Biological Engineering (AIMBE), a member of EU Academy of Sciences, the Council for Foreign Relations and the US Academy of Medicine Forum on Global Health. He served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare and is an Ex-Officio Member of the Bipartisan Commission on Biodefense.
Edward Abraham, PhD
President, Precision Medicine Coalition
Edward Abrahams, Ph.D., is the President of PMC. Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to more than 200 today.
Previously, Dr. Abrahams was the Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania's investment of $200 million to commercialize biotechnology in the state. Earlier, he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.
Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, as an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for Representative Edward J. Markey.
The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.
Deepak Asudani, MD, MPH, MBBS
Medical Director, HM International Patients' Program, UCSD; Director, Global Health Initiatives, UCSD; Clinical Professor of Medicine, UCSD
Dr. Deepak Asudani completed a residency in Internal Medicine from New York Medical College, Metropolitan Hospital Center, where he also served as assistant chief medical resident. He earned his Bachelors in Medicine and Bachelors in Surgery medical degree (MBBS) from the University of Rajasthan – Ravindra Nath Tagore Medical College in Udaipur, India. He holds a Masters in Public Health from the University of Massachusetts in Amherst, Mass. Dr. Asudani is a Certified Physician Executive (CPE) from the Credentialing Committee in Medical Management/American Association of Physicians Leadership, and holds certification in Genetics and Genomics from Stanford University Center for Professional Development, Palo Alto, CA. He is also an alumnus of UC San Diego Health Leadership Academy and Harvard Kennedy School of Government, Executive leadership program.
Dr. Asudani is board-certified in internal medicine, is currently a Clinical Professor of Medicine at University of California, San Diego and is engaged in several academic, clinical, and leadership responsibilities. He serves as Vice Chief of Division of Hospital Medicine at UCSD and also is Medical Director for UCSD's International Patients' Program. He is part of several UC San Diego health steering committees and also multiple Division of Hospital Medicine committees.
Jason J. Luke, MD, FACP
Associate Professor, University of Pittsburgh Medical Center, Director of Cancer Immunotherapeutics, Hillman Cancer Center
Jason J. Luke, M.D., F.A.C.P. is an Associate Professor of Medicine at the University of Pittsburgh Medical Center and Hillman Cancer Center where he is the Director of the Cancer Immunotherapeutics Center. Dr. Luke specializes in early phase drug development for solid tumors (particularly novel immunotherapeutics and biomarkers of immunotherapy activity) as well as the management of cutaneous oncology, particularly patients with melanoma. Dr. Luke has been a lead national investigator on clinical trials of immunotherapies including but not limited to anti-PD1/L1, CTLA4, many secondary checkpoints, bispecific approaches (checkpoint, CD3 and cytokine), metabolism modifiers (IDO, A2Ar/CD73/CD39 and arginase), innate agonists of STING, TLRs and oncolytic virus as well as solid tumor cellular therapies (TCRs and CART). Dr. Luke has been a major contributor toward the investigation of radiation and the microbiome in relation to cancer immunotherapy. Dr. Luke's major translational research focus leverages large scale informatics to advance cancer immunotherapy. Dr. Luke received his M.D. from Rosalind Franklin University of Medicine and Science in Chicago. He then pursued internship and residency at the Boston University Medical Center followed by medicine and medical oncology fellowships at Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center in New York City. Following fellowship, Dr. Luke was a tenure-track, Type 1 Instructor in Medicine at Harvard Medical School as well as Staff Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston. Thereafter Dr. Luke was an Assistant Professor at the University of Chicago. Dr. Luke is actively involved in several professional societies including the Society for Melanoma Research, the Society for Immunotherapy of Cancer, American Association for Cancer Research and the American Society for Clinical Oncology (ASCO). Dr. Luke has served as the chair of the education committee and as a member of the scientific committee for the melanoma track of the ASCO annual meeting. Dr. Luke has received several awards for research and clinical care including the Melanoma Research Foundation Humanitarian Award, Crain's 40 under 40, Department of Defense Career Development Award, Paul Calabresi Career Development in Clinical Oncology Award (K12), ASCO Merit Award as well as Young Investigator Awards from the Melanoma Research Alliance, the Cancer Research Foundation and the Conquer Cancer Foundation of ASCO. Dr. Luke's research has been supported by ASCO, the National Comprehensive Cancer Network and the National Cancer Institute.
Hakan Sakul, PhD
Vice President, Head of Diagnostics, Worldwide R & D, Pfizer Inc.
Hakan leads Pfizer's Companion Diagnostics efforts across the Worldwide R&D organization and is also responsible for Pfizer's internal Biobank group. His formal education includes BS (1983) and MS (1984) degrees from Ankara University in Turkey, PhD (1990) in Quantitative Genetics from the University of Minnesota as a Rotary Foundation Scholar, and postdoctoral studies in genetics at the University of California-Davis (1990-94).
Hakan worked in the biotech industry in human genetics and statistical genetics fields across multiple disease areas before moving to Parke-Davis Pharmaceuticals in 1998 to direct human genetics, statistical genetics and pharmacogenetics programs. Following the merger of Warner-Lambert/Parke-Davis with Pfizer, he has held positions of increasing responsibility in Clinical Pharmacogenomics, Molecular Profiling, and Translational Oncology. Hakan interacted closely with Pfizer's Executive Leadership Team and the Board of Directors to define and implement Pfizer's current companion diagnostics strategy. One of his most significant professional accomplishments was to lead the companion diagnostics program for Xalkori® (Crizotinib), Pfizer's flagship program in companion diagnostics. Hakan served on the clinical development and drug/diagnostics submission teams and led the companion diagnostics program to a successful delivery, resulting in simultaneous FDA approvals of both the drug and the companion diagnostic test in 2011.
Hakan was then promoted to his current role to provide companion diagnostics leadership across Pfizer's pharmaceutical pipeline. He led the internal efforts that resulted in companion diagnostics partnerships with Dako/Agilent and Siemens Healthcare Diagnostics, among others. Hakan's contributions to precision medicine and companion diagnostics have been widely recognized through both internal and external awards, frequent speaking engagements, and press coverage. He is the author of over 30 referred scientific articles as well as many other papers, abstracts and book chapters.
Hakan is keenly interested in technologies for identification of patient sub-groups for targeted treatments and development of companion diagnostics to advance Precision Medicine for the improvement of individualized health care. He is an active member of civic clubs, and enjoys cycling, soccer, and stand-up paddle-boarding.
Adrian Lee, PhD
Director, Institute for Precision Medicine, Pittsburgh Foundation Chair, University of Pittsburgh
Dr. Adrian Lee is the Pittsburgh Foundation Chair and Director of the Institute for Precision Medicine (IPM), a joint effort by UPMC and the University of Pittsburgh to move biomedical research into personalized well-being and clinical care. He is also Professor of Pharmacology & Chemical Biology and Human Genetics at UPMC Hillman Cancer Center.
Dr. Lee received B.Sc. and Ph.D. degrees in England, and came to San Antonio, Texas for his postdoctoral studies. He was subsequently recruited to Baylor College of Medicine and to the University of Pittsburgh in 2010.
Since his recruitment to the University of Pittsburgh in 2010, Dr. Lee has had a key role in shaping precision medicine research at the University of Pittsburgh and personalized care at UPMC. An example of the early progress in precision medicine at Pitt and UPMC is research and implementation of pharmacogenomics, and development of computational systems and architecture for sharing of clinical and genomic data both at the University of Pittsburgh and in the UPMC healthcare system. In cancer, efforts are underway to enhance genomic testing and use of targeted therapies.
The goal of Dr. Lee's laboratory is to translate basic cell and molecular research findings into the understanding and treatment of breast cancer. Dr. Lee has examined the effect of intratumor heterogeneity on prognostic tests in breast cancer, and is currently leading an effort to sequencing metastatic breast cancers to identify vulnerabilities for novel precision therapies. Dr Lee has published over 180 peer reviewed research articles. His laboratory is supported by funding from the NIH, Department of Defense, Susan G. Komen for the Cure, Breast Cancer Research Foundation, and other sources. Dr. Lee serves on numerous national peer-review committees and is on the Editorial Board of several journals. In 2018 Dr. Lee was awarded the Terri L Chapman award from Susan G. Komen, the PNC Elsie Hillman Distinguished Scholar award, and the University of Pittsburgh Biomedical Graduate Scholar Association (BGSA) Distinguished Mentor Award.
Nicholas (Nic) Dracopoli, PhD
Chief Scientific Officer, Delfi Diagnostics
Nicholas (Nic) Dracopoli, Ph.D. is Chief Scientific Officer at Delfi Diagnostics, a seed stage cancer diagnostics company based in Baltimore, MD. Previously he led oncology translational science teams at Bristol-Myers Squibb and Janssen. Prior to joining the pharmaceutical industry, he spent several years in the biotechnology industry at Sequana Therapeutics.
Nic obtained his bachelor's degree and doctorate from the University of London and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center in New York City, NY and the Massachusetts Institute of Technology (MIT) in Cambridge, MA. Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center and as a Section Chief at the National Center for Human Genome Research at the National Institutes of Health. Nic has authored more than 70 scientific publications and has extensive experience in the fields of genomics, molecular biology and cancer research.
Adrijana Kekic, PharmD
Program Director of Education, Outpatient Pharmacy Mayo Clinic Department of Pharmacy, Phoenix
Adrijana Kekic, Pharm D, is a Program Director of Education, Outpatient Pharmacy at Mayo Clinic in Phoenix, Arizona. She is active in clinical care, research and lecturing and has been involved in development of pharmacogenomics services and education. She is a licensed pharmacist in Arizona.
Dr. Kekic earned the Doctor of Pharmacy degree from Midwestern University College of Pharmacy in Glendale, Arizona. She is board certified ambulatory care pharmacist through Board Pharmacy Specialties (BPS) and a member of BPS Ambulatory Care Committee. She holds a certification in Pharmacogenomics from University of Florida College of Pharmacy and is pursuing a Genomic Medicine certification from Stanford University.
Adrijana has served as an adjunct faculty at Midwestern University College of Pharmacy and an instructor, preceptor and residency preceptor at Mayo School of Medical Science. She is involved with several pharmacogenomics research projects and studies in palliative care, transplant care, anesthesia and cardiology. She sits on Pharmacogenomics Task Force at Mayo Clinic.
With two decades of clinical experience and expertise in medication therapy management , Adrijana continues to advance pharmacy practice and pharmacy leadership. She is a founder of a networking platform dedicated to high impact professional women in healthcare. She lives in Arizona with her husband and son, where they enjoy hiking. Besides pharmacogenomics, her interest include languages, history, visual arts, martial arts and healthy living.
David Roth, MD
Simon Flexner Professor and Chair of Pathology and Laboratory Medicine, Director, Penn Center for Precision Medicine, University of Pennsylvania Perelman School of Medicine
David B. Roth, MD, PhD, joined Penn Medicine in 2011 as the Simon Flexner Professor and Chair of the University of Pennsylvania Perelman School of Medicine's Department of Pathology and Laboratory Medicine. Previously he was the Irene Diamond Professor of Immunology, Chair of the Department of Pathology, and Director of the MD/PhD Program at NYU Langone Medical Center. Around 2006, Roth's lab had generated genetically engineered mice that rapidly developed lymphomas that displayed incredible levels of genomic instability by disabling some of the regulatory controls associated with the normal mechanism of antigen receptor gene assembly. Every animal developed lymphoma within a few weeks, and, to understand the mechanism, the Roth Lab sought to characterize the genomic alterations in the tumor cells. To accomplish this, the lab began to develop capabilities for detecting and characterizing genomic rearrangements by "next generation sequencing" or NGS.
He moved to Penn in 2011 to take the Chair of the Department of Pathology and Laboratory Medicine. As part of his continuing efforts to bolster next-generation sequencing diagnostics, he set up the Center for Personalized Diagnostics, a joint effort between the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center. He is a Fellow of the College of American Pathologists, an elected member of the American Association of Physicians, and an elected member and past president of the American Association of University Pathologists.
In 2016, David was named the founding Director of Penn's new Center for Precision Medicine. The mission of this new Center is to take advantage of Penn's many strengths in biomedical research, developing synergies with our clinical programs to create and implement precision medicine-based clinical care pathways. One of the main roles of the Center will be to provide and organize the resources to allow us to design, test, and implement systems that allow each individual patient to receive the correct treatment (or prevention) at the right time.
Stephen Kingsmore, MD, DSc
President and Chief Executive Officer, Rady Children's Institute for Genomic Medicine
Dr. Stephen F. Kingsmore is President/CEO of Rady Children's Institute for Genomic Medicine where he leads a multi-disciplinary team of scientists, physicians and researchers who are pioneering the use of rapid Whole Genome Sequencing to enable precise diagnoses for critically-ill newborns.
Among his achievements, Dr. Kingsmore holds the Guinness World Record for achieving the fastest molecular diagnosis using whole genome sequencing in just 19.5 hours.
Before being selected to lead RCIGM, he was the Dee Lyons/Missouri Endowed Chair in Genomic Medicine at the University of Missouri-Kansas City School of Medicine and Director of the Center for Pediatric Genomic Medicine at Children's Mercy Hospital, Kansas City. Dr. Kingsmore received MB ChB BAO BSc and DSc degrees from the Queen's University of Belfast. He trained in clinical immunology in Northern Ireland and did residency in internal medicine and fellowship in rheumatology at Duke University Medical Center.
Ron Mazumder, PHD, MBA
Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics Genentech, Inc.
Abhijit "Ron" Mazumder obtained his B.A. from The Johns Hopkins University, his PhD from the University of Maryland, and his MBA from Lehigh University. After working in several biotech companies, he joined Johnson & Johnson in 2003 and led molecular diagnostics programs and biomarker collaborations. In 2008, he joined Merck as a Senior Director and Biomarker Leader in External Discovery where he was responsible for the development of pharmacodynamic and predictive biomarkers. Ron rejoined Johnson & Johnson in 2010 and led the development of companion and complementary diagnostics across the therapeutic pipeline. In October 2016, he joined Genentech where he is currently Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics.
Kathryn Phillips, PhD
Professor, Health Economics and Health Services Research, Department of Clinical Pharmacy, UCSD
Kathryn A. Phillips, PhD, is Professor of Health Economics and Health Services Research in the Department of Clinical Pharmacy at UCSF. A leader in the application of new technologies to improve healthcare, she is the Founding Director of the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS). She is a core faculty member in the UCSF Philip R. Lee Institute for Health Policy Studies and UCSF Helen Diller Family Comprehensive Cancer Center, and is affiliated with the Institute for Human Genetics, Department of Epidemiology and Biostatistics, Baker Computational Health Sciences Institute, and Global Health Sciences.
Kathryn focuses on the value of new technologies and how to most effectively and efficiently implement them into health care. Her core specialty is personalized (or precision) medicine — a new era of healthcare where medical interventions can be tailored to individual patients based on their unique genetic make-up. Her work spans multiple disciplines, including basic, clinical and social sciences, and brings together leading experts in academia, industry, healthcare, payers, and government. Her pioneering research on the application of health services research to personalized medicine has revealed insights on how to bridge the gap between emerging technologies and their use in the clinic. Kathryn led one of the earliest studies on the societal implications of pharmacogenomics, underscoring its potential to reduce the incidence of adverse drug reactions (JAMA, 2001). Kathryn has also conducted seminal work on HIV, as her analysis of HIV home testing informed the FDA's decision to approve the first home collection HIV test (New England Journal of Medicine, 1995).
Kathryn has published over 150 peer-reviewed articles in major journals, including JAMA, New England Journal of Medicine, and Health Affairs and has had continuous funding from the U.S. National Institutes of Health as a Principal Investigator for over 25 years. She currently serves on the editorial boards for Health Affairs (rated as the top policy journal), Value in Health (a leading outcomes research journal), JAMA Internal Medicine, Genetics in Medicine (section editor), and leading journals on precision medicine. Kathryn has served on national and international scientific advisory committees and workshops including the Board of Directors for GenomeCanada, National Academy of Medicine, Food and Drug Administration, Centers for Disease Control and Prevention, and the President's Council of Advisors on Science and Technology. She has also served as an advisor to various international and industry organizations, including ~50 biotechnology companies and venture capital firms. In 2016, she was awarded a Rockefeller Foundation award to pursue work on global health. She is currently serving as Chair of the Global Economics and Evaluation of Clinical Sequencing Working Group, and is serving on an evidence review committee for the Institute for Clinical and Economic Review (ICER).
Katherine (Katie) Johansen Taber, PhD
Senior Director, Clinical Development, Myriad Women's Health
Katherine (Katie) Johansen Taber, PhD, is Director of the American Medical Association's Personalized Medicine program which focusses on educating physicians about the clinical implementation of genetics and on identifying and managing genetics policy issues affecting health care providers. She also advises the AMA Board of Trustees and the House of Delegates on genetics issues such as the oversight of genetic testing, gene patenting, stem call research, and newborn screening.
Katie is a member of the Institute of Medicine's Roundtable on Translating Genomics-based Research for Health, the VA National Research Advisory Council, the El Camino Hospital Genomic Medicine Institute Advisory Council, and a number of other genetics-focused workgroups. She serves as the Assistant Secretary for the AMA's Council on Science and Public Health and also represents the AMA as a Dissemination and Implementation Partner for the United States Preventive Services Task Force. Katie earned her PhD in Molecular, Cell and Developmental Biology at the University of California, Los Angeles, and conducted post-doctoral research at the USDA. She has held teaching appointments at UCLA, California State Polytechnic University, University of Idaho, and Columbia College Chicago.
Marielena Mata, PhD
Senior Director and Diagnostic Lead, Oncology Program, Pfizer
Marielena Mata, PhD is Director and Diagnostic Lead at Pfizer, where she Leads the development and commercialization efforts of companion diagnostics for Oncology assets from early to late development. Prior to Pfizer, Dr. Mata was Head of Personalized Medicine and Companion Diagnostics at GSK where she was responsible for implementation of the Precision Medicine strategy across the GSK portfolio encompassing technical, development, regulatory, commercial, IP and business development efforts. Previously, at Janssen R&D, Inc. Dr. Mata was responsible for the design and implementation of biomarker strategies for Oncology assets, where she led the development of Circulating Tumor Cell based assays as companion diagnostics as well as the development of next generation circulating tumor cell isolation technologies based on microfluidics. Earlier, she established and managed the Biomarkers biobank. In addition to her work in Oncology drug development, Maty, as she is known, has a strong interest in women's career development and mentorship and is the recipient of the AWIS-PHL Elizabeth Bingham Mentoring Award. Dr. Mata obtained a BA in Biology at the University of North Carolina at Greensboro and her PhD and postdoctoral training in Immunology at the University of Pennsylvania.
Lincoln Naduald MD, PhD
Executive Director, Precision Medicine & Precision Genomics, Intermountain Healthcare
Lincoln Nadauld, MD, PhD, is the Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare where he oversees the clinical implementation of genomic cancer medicine across its 22 hospitals and 180 physician clinics. Dr. Nadauld completed clinical training in Medical Oncology at Stanford University School of Medicine, where he also completed a postdoctoral fellowship in solid tumor genomics. He remains on the research faculty at Stanford, focusing on cancer genomics and personalized medicine. His work has been published extensively. He also serves on the Board of Directors of the Gastric Cancer Foundation and regularly reviews grant applications on behalf of the Department of Defense. Dr. Nadauld recently participated in the Precision Medicine Initiative Summit and roundtables at the White House with former President Barack Obama. He also attended former Vice President Joe Biden's Cancer Moonshot Summit, where the Oncology Precision Network (OPeN), spearheaded by Dr. Nadauld, was mentioned among the vice president's remarks. OPeN is a consortium of healthcare partners working to advance data-sharing in precision medicine, including genomic information and outcomes. Dr. Nadauld is married with five children, and enjoys attending their many activities and events, water sports, fishing, and other athletic pursuits.
Kamala K. Maddali DVM, PhD
President and Founder, Health Collaborations LLC
Dr. Kamala Maddali is a biotech, pharma, diagnostics and life sciences executive and board advisor with over 17 years of deep expertise in Precision Medicine implementing strategic initiatives across many Fortune 500 companies, most notably Merck and Co., Quintiles and Quest Diagnostics. She holds a Ph.D. in Pharmacology from the University of Missouri-Columbia and a doctorate in Veterinary Medicine from Tirupati, India. She currently is an executive advisor to companies focused in Precision Medicine, Artificial Intelligence and digital health companies in healthcare. Dr. Maddali won the 2016 Healthcare Heroes Finalist Award for "Innovation-Individual" category at NJBIZ. Dr. Maddali received many awards focused on "women empowerment in Healthcare" from several organizations in the USA. Dr. Maddali served as a Vice Chair for the Women in Bio (WIB) Philadelphia chapter. The Women In Bio organization promotes careers, leadership, and entrepreneurship for women in the life sciences. Dr. Maddali was invited in 2017 for the NYSE Closing bell ringing ceremony. Dr. Maddali was interviewed by CNBC in December 2018 on Precision Medicine advancements and Blockchain.
Steven M Anderson, PhD
Chief Scientific Officer, Covance; Senior Vice President, LabCorp
Dr Anderson is a Senior Vice President at Laboratory Corporation of America (LabCorp), and the Chief Scientific Officer for the Covance Drug Development business of LabCorp. He has been with the LabCorp organization for 26 years and has held a variety of positions including director of operations for ViroMed Laboratories, director of operations for Monogram Biosciences, director of operations for the Center for Molecular Biology and Pathology, director of operations for Integrated Oncology and Genetics, national director of Research and Development, and global head of LabCorp Clinical Trials. Dr Anderson is a member of a variety of professional societies including the American Association for Cancer Research, the American Society of Clinical Oncology and the Association for Molecular Pathology.
Dr Anderson's research interests are in the development and applications for molecular diagnostics, including several examples of companion diagnostics and pharmacogenomics assays. He has authored more than 175 articles and abstracts published in such journals as Genetics, Proceedings of the National Academy of Sciences, Clinical Chemistry, the Journal of Infectious Disease, Human Pathology, American Journal of Obstetrics and Gynecology, Oncogene, the Journal of the National Cancer Institute, Clinical Cancer Research, Breast Cancer Research, BMC Cancer, the Journal of Molecular Diagnostics, Archives of Pathology and Laboratory Investigation and Expert Reviews in Molecular Diagnostics.
He has a PhD in genetics from Iowa State University and was an American Cancer Society postdoctoral fellow at the Waksman Institute of Rutgers University.
Katherine Capps
Co-founder and Executive Director, GTMRx
As executive director, Katherine Capps provides leadership by supporting GTMRx Institute's mission and goals. She establishes and manages relationships with stakeholders across the health care spectrum. As a GTMR Institute Founding Board member, she works alongside other board members and collaboratively sets the strategy for the growth and activities of the organization.
Katie has a long history of collaboration in multi-stakeholder environments. As Health2 Resources' founder and president, she and her team have helped more than 35 clients meet advocacy, policy, outreach, marketing and awareness goals. H2R was instrumental in the launch of the Patient-Centered Primary Care Collaborative, lending expertise for organizational development and marketing and communications.
She has served on the board of the Washington Adventist Health Foundation, the Institute for Health and Productivity Management (advisory board), the Healthcare Industry Access Initiative and Emmi Solutions. She has served on the board of the National Business Coalition on Health and its national advisory board, and on the NCQA purchaser committee. She writes on topics relating to quality, health care cost, market-based health care reform and the value of shared health information.
Arturo Slava, MD, MSEd, FACP
Vice Chair, Medical Oncology, Cancer Treatment Centers of America (CTCA), Philadelphia, Chief Medical Advisor & Co-Founder, Massive Bio
Dr. Loaiza-Bonilla is Vice Chairman of the Department of Medical Oncology at Cancer Treatment Centers of America (CTCA) in Philadelphia, Pennsylvania. Dr. Loaiza-Bonilla is dedicated to comprehensive care for patients suffering from gastrointestinal malignancies, such as colon, esophagus, gastric, liver, pancreas, and neuroendocrine tumors. Dr. Loaiza-Bonilla earned a medical degree from the Universidad Nacional de Colombia in Bogotá, Colombia. Following medical school, he completed an Internship and Residency in Internal Medicine at Harbor Hospital Center in Baltimore, Maryland. Dr. Loaiza-Bonilla also completed a Fellowship in Hematology and Oncology at the University of Miami, Miller School of Medicine. Prior to joining CTCA, Dr. Loaiza-Bonilla was an Assistant Professor of Clinical Medicine at the Perelman School of Medicine at the University of Pennsylvania. During this time, he completed his master's degree in medical education at the same university. Dr. Loaiza-Bonilla has been published in several medical journals and oncology publications. He is also a reviewer and counselor for several journals, special interest groups, panels and academic competitions. He has also served as principal investigator and co-investigator for many large oncology clinical trials. Dr. Loaiza-Bonilla has been a member and held leadership positions for several medical organizations. These include the Pennsylvania Society of Oncology and Hematology, the American Society of Hematology, the American Society of Clinical Oncology, and the American Association of Cancer Research.
Roy Smythe, MD
Chief Executive Officer, SomaLogic
Roy Smythe, M.D., joined SomaLogic in November 2018 as Chief Executive Officer. During the course of his career, Dr. Smythe has been an internationally recognized surgeon, biomedical scientist, academician, health system administrator and healthcare business entrepreneur.
While in medical school at Texas A&M, he was a Charles A. Dana Foundation Scholar at the University of Pennsylvania School of Medicine and the Wharton School of Business. Following medical school, he trained in general surgery, surgical oncology and thoracic surgery and completed a postdoctoral research fellowship in molecular therapeutics at the University of Pennsylvania. His medical and translational research career then began at the University of Texas MD Anderson Cancer Center, where he was the recipient of NIH and numerous other funding awards. He subsequently chaired the Department of Surgery at Baylor Scott & White Health System and the Texas A&M Health Science Center College of Medicine, where he was the Roney Endowed Chair, and later became the Medical Director of Innovation and Executive Vice President for Institute Development before moving into expanded roles in corporate healthcare.
Dr. Smythe came to SomaLogic from Royal Philips, where he served as Global Chief Medical Officer for Strategy and Partnerships. Before joining Philips, he served as Chief Medical Officer at Valence Health, a Chicago-based healthcare company. He held the same title previously at AVIA, a healthcare technology accelerator.
A highly sought-after lecturer and the author of more than 300 papers, abstracts and essays in academic, literary and humanities publications, Dr. Smythe is also currently a member of more than 20 U.S. national learned societies.
Luis M. Lasalvia, MD
Vice President & Global Medical Officer, Siemens Healthineers
Dr. Luis Lasalvia, Vice President Siemens Healthineers, is pursuing effective, compassionate and patient centric healthcare. He has been guest speaker at approx. 500 conferences and events around the world, submitted several patents in the US and Europe, and authored more than 50 papers and articles in peer review journals, and other prestigious publications.
Entrepreneur and strategist with international background, has participated in projects in more than 50 countries in all continents. In precision medicine leads companywide though leadership, generating novel and action-oriented insights, proactively collaborating and working together with organizations and top leaders around the globe.
Has a unique mix of knowhow and experience in clinical and financial value. His clinical practice coupled with extensive experience in both pharmaceutical and medical device industries, pairs with startup advisory and venturing. Covered multiple roles as practicing physician, strategist, innovator, companywide clinical marketeer, corporate negotiator, and scouter.
Medical Doctor (Republic University, Montevideo), Master in International Business (Pompeu Fabra University, Barcelona), holds Postgraduate degrees in Business Administration and in Marketing, with entrepreneurship, risk management, and innovation executive studies at The Wharton School of Business, New York University, and Harvard Business School.
Kenna Mills Shaw, MD
Director, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (Khalifa Institute)
Dr. Shaw is executive director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (Khalifa Institute). She joined The University of Texas MD Anderson Cancer Center in 2013, bringing an extensive background in science leadership and education. Prior to joining MD Anderson, Dr. Shaw spent four years with The Cancer Genome Atlas (TCGA), a flagship project of the National Cancer Institute focused on accelerating understanding of the molecular basis of cancer. Dr. Shaw earned undergraduate degrees in Spanish and Biology at the College of William and Mary, and completed her doctoral degree in cell and developmental biology at Harvard University.
Yves A. Lussier, MD, FACMI
Chair, Biomedical Informatics, University of Utah School of Medicine
Yves A. Lussier, MD, FAMCI, is the Chair of Biomedical Informatics at University of Utah School of Medicine. As a professional engineer and physician-scientist, he is an international expert in translational bioinformatics and a pioneer in research informatics techniques including systems biology, data representation through ontologies, and high-throughput methods in personalized medicine.
Dr. Lussier comes to the University Utah from the University of Arizona, where he was the Associate Vice President for Information Science and Chief Knowledge Officer of the UArizona Health Sciences (UAHS), Founding Director of the Center for Biomedical Informatics and Biostatistics, and Professor of Medicine. During his time at UArizona, he developed novel programs in biomedical informatics, computational genomics, and precision health, as well as provided critical leadership to advance precision health approaches to health outcomes and healthcare delivery and in the development of big data analytical tools and resource services. Prior to his tenure at UArizona, Dr. Lussier was professor of medicine, bioengineering and biopharmaceutical sciences at University of Illinois at Chicago (UIC), and assistant vice president for health affairs and chief research information officer for the University of Illinois Hospital and Health Sciences System (2011-13). From 2006-2011, he was the associate director of informatics for the University of Chicago Comprehensive Cancer Center as well as co-director of biomedical informatics for the Clinical and Translational Science Award (CTSA)-funded Institute for Translational Medicine. From 2001-2006, Dr. Lussier was an assistant professor in the Departments of Biomedical Informatics and Medicine at Columbia University in New York.
Lussier's research group conducts pioneering hypothesis-driven computational modeling predictions in precision medicine that are then validated in vitro, in vivo and in clinical trials. As a leader of the fields of translational bioinformatics and of Data Science-augmented precision medicine, he has launched successful companies and international conferences, authored 185 publications, and delivered more than 100 invited presentations in precision medicine, systems medicine, and translational bioinformatics, including 28 opening keynotes at international conferences. He has been awarded $190,000,000 in grants as principal, core leader, or co-investigator, and mentored or co-mentored over 90 graduates, post graduate fellows, and junior faculty members, of which twelve are faculty members, seven obtained K-awards, and five obtained R awards. Dr. Lussier's honors include three IBM Faculty Awards, inducted Fellow of the American College of Medical Informatics (ACMI), 1st recipient of the Columbia University Faculty Mentoring Award, "Ambassador for Health Sciences" at the University of Sherbrooke (Canada), and 16 outstanding publication awards from the American Medical Informatics Association (AMIA), the International Society for Computational Biology (ISCB), and the Translational Bioinformatics Conference (TBC). In 2016, Dr. Lussier was invited among ten USA academic leaders invited by the White House for its Precision Medicine Summit.
Ruben Bonilla Guerrero, MD, DABMG, FACMG, FAACC, MB(ASCP), CGMBS
Chief Medical Officer, Innovative Gx
Dr. Ruben Bonilla-Guerrero serves as Innovative Genomics (IGx) Laboratories' Chief Medical Officer. He is a laboratory professional, who is Mayo Clinic trained in Clinical Pharmacology, Clinical Biochemical Genetics, and Molecular Biology, a Fellow of the American College of Medical Genetics, the American Association of Clinical Chemistry, and is an active member of several distinguished professional organizations. Dr. Ruben Bonilla-Guerrero board certified in Clinical Biochemical Genetics by the American Board of Medical Genetics (ABMG) and in Molecular Biology by the American Society for Clinical Pathology (ASCP), with expertise in clinical pharmacology, inborn errors of metabolism, genetics, vaccine development, and clinical pharmacogenomics. Having authored several peer-reviewed medical publications including book chapters, Dr. Bonilla-Guerrero is also the winner of the Henry Christian Award from the American Federation for Medical Research (2002) and the Mayo Clinic Department of Internal Medicine Outstanding Research Fellow Award (2003). Previously, Dr. Bonilla-Guerrero simultaneously served as Laboratory Director, Associate Medical Director, and Medical Director of Medical Affairs for the department of Genetics at Quest Diagnostics, as well as concurrently served as the Medical Director and Vice President of Medical Affairs at Admera Health. He is responsible for the clinical genomic-based testing at Innovative Gx Laboratories and leads the Medical Affairs team.
Burns C. Blaxall, PhD, FACC, FAHA, FISHR, FAPS
Executive Director, Precision Medicine, The Christ Hospital Health Network
Burns C. Blaxall, PhD, FAHA, FACC, FAPS is a Professor of Pediatrics in the Heart Institute at Cincinnati Children's Hospital Medical Center, where he serves as Director of Translational Science and Co-Director of the Heart Institute Research Core and Biorepository. Dr. Blaxall received his PhD in Pharmacology from the University of Colorado Health Sciences Center and completed his postdoctoral fellowship at Duke University Medical Center. He has received numerous academic honors, including the Early Career Investigator Award from the American Heart Association (AHA) and the Outstanding Achievement Award from the Founder's AHA Affiliate. He has extensive peer review service and chaired the Cardiomyopathy and Congestive Heart Failure NIH peer-review panel. His laboratory is focused on understanding the molecular signals associated with the onset and progression of heart failure and myocardial and renal fibrosis, with a particular emphasis on identifying novel therapeutic approaches.
Mark Fidock, PhD
Vice President, Diagnostic Development, Precision Medicine and Biosamples, R&D Oncology Unit, AstraZeneca
Dr Mark Fidock is Vice President of Diagnostic Development, Precision Medicine and Biosamples within the R&D Oncology Unit at AstraZeneca, located in the UK. He received his PhD from the University of East Anglia in Molecular Pharmacology. Mark gained extensive experience in drug development holding senior positions at Pfizer and a global CRO where he built a successful translational medicine department.
Mark joined AstraZeneca in 2013 appointed to the role of Head Diagnostic Development with overall accountability for all clinical testing activities and scientific investigations that enable diagnostic development for regulatory approval. He leads a global multidisciplinary team in the delivery of Companion Diagnostics across both the AZ Oncology and Biopharmaceuticals clinical portfolio.
By 2020, Mark's leadership in Precision Medicine had contributed to >40 diagnostic approvals in 3 major markets linked to 4 AZ targeted therapies. Achieving industry firsts such as a companion diagnostic for circulating tumour DNA to maximise patient access to our targeted therapy in Oncology and the first point-of-care complementary diagnostic in Biopharmaceuticals to enable better disease management and physician decision making.
During the pandemic Mark provided the strategic leadership and was accountable for the global operational delivery of laboratories within an internal PCR testing programme for COVID-19; this included gaining approvals for US CLIA and Europe ISO17025 lab accreditations. This programme ensured AZ employees had a safe working environment and maintained the supply chain of critical medicines for patients.
Mark has published more than 35 peer-reviewed articles in scientific journals and edited the Handbook of Biomarkers and Precision Medicine. As an internationally recognized expert in Precision Medicine, he holds an honorary position at the University of Cambridge and a member of the Institute of Translational and Stratified Medicine, Plymouth, and Radboud University Medical Centre scientific advisory boards.
PMLS SIGN UP
Receive the information about our 2023 conference speakers, schedule and registration.


The Dodge County Flea Market and Craft Fair continues to grow. Vendors and shoppers flock to trade vintage, antique and unique items. It's like a walk down memory lane as you see items from the past all for sale from local vendors. Plus it's a great place to find one of a kind hand made gifts! Craft Fair vendors always have a variety of items for many different tastes. Markets are held RAIN or SHINE with indoor and outdoor spaces, FREE Admission and FREE Parking! Vendors should contact Mary Edwards to reserve booth space. Feel free to post your comments and questions in the reply section below.
Hi, i was wondering if there are anymore booths available and if so what do you do to reserve one?
No need to reserve a booth, spots are first come, first serve virtually unlimited room throughout several buildings at the Fairgrounds. Only limit is one direct sales person per company. Vendors pay $20 for a 12′ wide inside spot and $15 outside, set-up starts at 6am.
Exhibitor spots are $20 indoors, $15 outdoors. Spots are about 12′ wide and are first come, first pick (we will not run out of room). You can purchase several spots if you have a lot to sell. Mary Edwards our event coordinator will collect payment and get your contact information the day of the event. Tons of room, event is growing by leaps and bounds!
Mary, I would like an outside space again I love selling here.
Are there quite a few vendors & attendees? I've never been to it. Thanks!
At the end of last year we were averaging 40 to 50 vendors, always a good variety!


« Save Money with Educator Discounts!
This retort, and the whining that went with it, conjured up my Evil Twin who suggested household chores, "If there's time to lean, it's time to clean!" Funny how that made them forget about being bored. Their amnesia was only temporary.
In my experience, bouts of boredom flare up when kids are between projects. What they really want are suggestions to get them jump-started on a new area of interest. Coming up with ideas for new explorations can be daunting. You may feel like Old Mother Hubbard – without a bone to toss them. Not only is your "idea cupboard" bare – you may be too tired or exhausted to care.
Let's face it, we can all get a little bored with our homeschool routine. While a Starbuck's mocha latte will jolt you into action – it wears off. There is a better solution – something more helpful, long lasting and nerve soothing. Attend a homeschool conference!
It will revitalize you and your children. You'll be surrounded by homeschool parents who will affirm the soundness of your decision to educate your kids at home. The keynote speakers will provide you with food for thought. The workshops on every subject imaginable will fill your cupboard with new ideas, methods, and resources for learning with your children at home.
The vendor hall provides opportunities for hands-on experience with educational supplies, curricula, games, and toys. Boredom-busting activities for kids and teens abound. Solutions for every homeschool dilemma are offered by caring and supportive veteran homeschool parents.
Between now and September is homeschool conference season. My recommendation for those who have run out of ideas or are suffering from homeschool apathy, burnout, or boredom is to attend as many as you can. Your spirit will be renewed, your enthusiasm restored, and your homeschool cupboard will runneth over.
If you would like a directory of homeschool conferences, seminars, and events taking place throughout the U.S., The Old Schoolhouse Magazine website provides a comprehensive list of both Christian and secular events.
Go – it's one of the best investments you'll make for your family!
Do you know of other homeschool conferences taking place between now and September 30, 2009? You are welcome to post a notice about it in the comments section below. If you include a link to it, be sure it contains the entire url, for example: http://www.Homefires.com. Also, please indicate if the conference is Christian or nonsectarian/secular.
Copyright 2009, Diane Flynn Keith, All Rights Reserved.


text:
Senate approves bipartisan, $1 trillion infrastructure bill, bringing major Biden goal one step closer
Democrats along with 19 Republicans approved the public-works package in a Tuesday morning vote, teeing it up soon for the House
Sens. Rob Portman (R-Ohio) and Kyrsten Sinema (D-Ariz.) speak at a news conference after a procedural vote for the bipartisan infrastructure framework on July 28. (Alex Wong/Getty Images)
By Tony Romm
August 10, 2021 at 6:32 p.m. EDT
The Senate on Tuesday approved a roughly $1 trillion proposal to improve the nation's roads, bridges, pipes, ports and Internet connections, advancing a historic burst in federal spending after years of failed attempts on Capitol Hill to invest anew in the country's aging infrastructure.
The 69-to-30 vote follows weeks of turbulent private talks and fierce public debates that sometimes teetered on collapse, as the White House labored alongside Democrats and Republicans to achieve the sort of deal that had eluded them for years. Even though the proposal must still clear the House, where some Democrats recently have raised concerns the measure falls short of what they seek, the Senate outcome moves the bill one step closer to delivering President Biden his first major bipartisan win.
The package, nearly half of which constitutes new spending, would mark the most significant investment in the country's inner workings since Congress marshaled a massive yet smaller rescue bill in the shadow of the Great Recession. It would combine lawmakers' desire for immediate, urgently needed fixes to the country's crumbling infrastructure with longer-term goals to combat challenges including climate change.
The bill proposes more than $110 billion to replace and repair roads, bridges and highways, and $66 billion to boost passenger and freight rail. That transit investment marks the most significant infusion of cash in the country's railways since the creation of Amtrak about half a century ago, the White House said.
The U.S. Senate is expected to approve President Biden's $1.2 trillion infrastructure bill as early as Aug. 10. (Reuters)
Which Biden priorities are included in the bipartisan infrastructure bill?
The infrastructure plan includes an additional $55 billion to address lingering issues in the U.S. water supply, such as an effort to replace every lead pipe in the nation. It allocates $65 billion to modernize the country's power grid. And it devotes additional sums to rehabilitating waterways, improving airports and expanding broadband Internet service, particularly after a pandemic that forced Americans to conduct much of their lives online.
Lawmakers also agreed to authorize a significant tranche of funding to improve the environment and respond to the oft-deadly consequences of a fast-warming planet. The aid includes $7.5 billion to build out a national network of electric-vehicle charging stations, a major priority for Biden, who has worked to advance the next generation of emissions-friendly vehicles. And it apportions $47 billion to respond to wildfires, droughts, coastal erosion, heat waves and other climate crises that previously have wrought significant economic havoc nationwide.
"America's often had the greatest prosperity and made the most progress when we invest in America itself," Biden said Tuesday in a speech heralding its passage, stressing the investments ultimately would create jobs. "And that's what this infrastructure bill does, with overwhelming support from the United States Senate."
The White House helped craft the proposal alongside its chief congressional sponsors, Sens. Kyrsten Sinema (D-Ariz.) and Rob Portman (R-Ohio). The two for weeks shepherded a group of 10 lawmakers from both parties toward a compromise that could thread a needle — proffering the massive investments Biden initially sought without raising alarm among spending-wary Republicans.
The result is a bill that is less than the roughly $2.2 trillion American Jobs Plan that Biden put forward this spring, but one that every chamber Democrat along with 19 Republicans, including Minority Leader Mitch McConnell (R-Ky.) could still support. Democratic leaders have pledged to pursue the rest of their spending priorities as part of a second $3.5 trillion budget measure that GOP lawmakers oppose.
"It will improve the lives of all Americans," Portman said in a floor speech over the weekend as lawmakers prepared to vote. "People do expect here in America, [with] this great economy we have, we should also be able to lead the world in infrastructure. But we don't."
Democrats release $3.5 trillion budget blueprint as Senate finishes infrastructure debate
Lawmakers jettisoned Biden's plan to raise taxes on corporations to finance the new infrastructure investments, a nonstarter for Republicans, who strained to protect the tax cuts they instituted under President Donald Trump four years ago. Instead, their new legislative effort relies on a mix of odd measures — and potential budgetary gimmicks — to try to offset its cost. An official analysis of the bill by the Congressional Budget Office on Thursday found that lawmakers fell short, threatening to add more than $250 billion to the deficit over the next decade.
The sour score set the stage for one of the only significant fights over the bill. The spending concerns prompted Sen. Bill Hagerty (R-Tenn.) to block the chamber from adopting the infrastructure measure swiftly over the weekend, arguing that Democrats should not be able to expedite passage of a work product that he said had not been paid for in full.
"We must fight to preserve our American system and the American Dream, not — in a tornado of hurried legislative activity — seal its decline," Hagerty said in a floor speech Saturday.
In doing so, Hagerty's opposition opened a rift between Democrats and Republicans over potential amendments, because changes to the bill's timeline as well as its text required some measure of unanimous consent. The standoff ultimately prevented senators from making at least one key change to the bill, targeting highly disputed rules that require cryptocurrency investors and brokers to report more information to the Internal Revenue Service for tax purposes.
Broadly, though, lawmakers managed to avoid the same intractable fights that have scuttled other legislative efforts this year to regulate guns, change voting laws and investigate the riot at the Capitol on Jan. 6. An earlier effort between the White House and top GOP senators to work out a compromise on infrastructure similarly fell short, illustrating the fragile victory that the Senate achieved in securing a bill with Biden's backing.
At the same time, the moment of political accord proved to be short lived. Immediately, Senate Democrats pivoted to debate on their roughly $3.5 trillion budget that includes entire categories of spending that infrastructure negotiators omitted from their efforts. Republicans unanimously oppose the measure, which opens the door for Democrats to craft legislation that would expand Medicare, invest new sums to combat global warming and boost federal programs that aid parents and children.
Unlike their approach with the infrastructure bill, Democrats intend to advance the final bill through a process known as reconciliation, which means they need to attain a majority to proceed rather than the usual 60 votes. That requires the party's lawmakers to stick together as they sort through thorny political issues, especially around how to pay for the package and how large it should be.
"Other parts of our infrastructure, not addressed by this bipartisan bill, still need focused attention and help," Senate Majority Leader Charles E. Schumer (D-N.Y.) said Tuesday. He added that the Senate intends to adopt a budget that makes "generational transformation in these areas."
Adding to the challenge, though, is that some House Democrats have emphasized in recent days that they aren't willing to begin debating infrastructure until the Senate completes its work on the budget.
Rep. Pramila Jayapal (D-Wash.), the leader of the Congressional Progressive Caucus, reiterated that pledge this week on behalf of her powerful bloc of lawmakers, without whom House Speaker Nancy Pelosi (D-Calif.) does not have the votes to proceed. In a recent interview, Jayapal stressed there are "not going to be votes for the bipartisan bill without votes for the reconciliation bill."
Senate infrastructure bill would add hundreds of billions of dollars to the deficit, CBO says
The successful outcome on infrastructure Tuesday comes after months of bickering between lawmakers and the White House over Biden's broader agenda, which he termed "Build Back Better," dating back to the 2020 presidential campaign. Biden sought to deliver Washington its long-sought infrastructure ambitions after years of false starts under Trump, who could never coalesce Congress around a deal.
The legislative saga began in the spring, after Biden released his jobs plan and invited GOP lawmakers led by Sen. Shelley Moore Capito (R-W.Va.) to the White House for a series of ill-fated talks. The two sides after weeks of discussions could not agree on a total amount for infrastructure spending, much less how to pay for it, leading Biden in June to end negotiations amid public sniping between the two parties.
As that endeavor collapsed, a second group of 10 Democratic and Republican senators began to huddle on their own in pursuit of a deal. Lawmakers including Democratic Sens. Jon Tester (Mont.) and Mark R. Warner (Va.) and Republican Sens. Mitt Romney (Utah) and Susan Collins (Maine) met alongside Biden's top aides in a series of late-night sessions at the Capitol — often over bottles of wine — as they hammered out what became a blueprint for a $1.2 trillion outline released in late June.
The fraught process nearly fell apart only days after they announced their agreement. Biden had threatened at a public event that he could veto a bipartisan public-works deal unless Congress also adopted a larger budget that included his other spending priorities, including his roughly $1.9 trillion families plan. Republicans saw the comment as evidence the White House might not be negotiating in good faith, prompting the president to issue a corrective statement that eventually got the two sides back on track.
It still took weeks of haggling — and pressure applied from Schumer as well as the looming summer recess — before Democrats and Republicans could produce the 2,702-page bill they adopted Tuesday. They had warred in private over differences about how to spend the money in areas like transit and broadband, and how to pay for the spending. Republicans at one point even upended the talks over their concerns about a plan to raise funding for infrastructure through enhanced enforcement of federal tax laws, resulting in the proposal's removal from the deal.
But when lawmakers gathered on the Senate floor to reveal their final product — delivering several speeches in early August touting the wide-ranging benefits of their proposed investments — they hailed their long-sought accomplishment as a sign the Senate is still a functional body.
"I know it has been difficult, and I know it has been long, and what I am proud to say is that is what our forefathers intended," Sinema said.

redpajama_set_name: RedPajamaCommonCrawl


text:
Q: Justification of Integrating an $L^1$ Function with Singularity The function $f_p:[0,1]\rightarrow \textbf{R}^{\geqslant 0}$, $0<p<\infty$, $f_p(x):=px^{p-1}$ has a singularity at $x=0$. However, it's improper Riemann integral converges, i.e.
\begin{align*}
\lim_{h\rightarrow 0}\int_h^1\,px^{p-1}\,dx = \lim_{h\rightarrow 0}(1-h^p) = 1
\end{align*}
Therefore $f\in L^1_{\text{loc}}[0,1]$, but I would like a sanity check that this is sufficient to be in $L^1[0,1]$.
More generally, under what conditions can we ignore singularities when considering $L^p$ functions. If we can make the improper Riemann integral converge  is that always sufficient for being in $L^p$?

A: A function with a finite improper Riemanm inetgral need not be in $L^{1}$. An example is $\frac {\sin x} x$ on $(0,\infty)$. However, if  a non-negative measurable function has an improper Riemann integral then it is in $L^{1}$ by Monotone Convergence Theorem.

redpajama_set_name: RedPajamaStackExchange


Now, in the brick and mortar planet hot locations are extremely costly to obtain. This is simply simply because the owner knows that it is a hot home and sets his/her rates accordingly. Mega hot on the net properties are no diverse. The laws of provide and demand drive their prices upward to the point that tiny companies just cant afford to compete for those spots. So, if you have attempted to get noticed online with a budget of much less than one hundred dollars, you undoubtedly have identified that you are out of luck.
Cease carrying out that. Qualified marketers realize this. You cant afford it.
The great online marketing campaign really should be focused on investing as tiny as probable, while obtaining as substantially as doable in return. Expert marketers comprehend this. Amateur marketers typically dont grasp this until they have sunk thousands of dollars into campaigns that only create a few dollars if they are fortunate. Thats named going into the red but let critique. OK, Alright, you know what a banner ad is and you believe you know what you want it to say. That is a start, but it is only a start. There are other more pressing things to take into account. The banner ad is a very critical piece of the marketing puzzle but exactly where you spot it makes all the distinction in the globe. In the brick and mortar globe of real estate, firms seek out buildings for their operations based on where it is positioned. Businessmen and businesswomen often attribute success to location, place, location.
As previously stated, provide and demand drives the price of advertising up extremely immediately. You have to uncover the internet sites that are destined to take off and get in Ahead of they go major. Numerous little advertisers wait about and finish up competing with the large boys as soon as the house goes hot. Quit carrying out that. You cant afford it. To get the world to take notice demands a specific level of advertising innovation and most marketers dont have it and subsequently do it incorrect.
Marketing on the web is the first issue marketers consider of when their organization is prepared to launch. Nevertheless, building a web page that places their item or service on show for the planet to see is a lot simpler than obtaining the world to really want to see it. The way to beat unfriendly marketing pricing structures is to be innovative in your ad placements. Appear for sites that are just starting and scoop up the ad spaces like a stock ready to blast off.
Finance Jobs Without A Degree – Now, in the brick and mortar world hot areas are incredibly pricey to obtain. This is simply simply because the owner knows that it is a hot property and sets his/her prices accordingly.


text:
In this section: Research and innovation
Atmospheric and Planetary Chemistry
Chemical Biology and Medicinal Chemistry
Colour and Polymer Science
Computational Chemistry and Chemical Physics
Crystallisation and Directed Assembly
Institute for Process Research and Development (iPRD)
Transforming Europe's drug discovery practice
How intelligent machines speed medicine manufacture
Reengineering the sugar forest
An innovative answer to capturing carbon
Mimicking nature for better drug discovery
Solving the Rubik's cube of medicinal chemistry
Astbury Centre for Structural Molecular Biology
Bragg Centre for Materials Research
This research group focusses on the application of assembly-based approaches for the generation of new functional materials.
When we look at nature, a fundamental feature of many of the materials or matter formed (which range from crystalline solids such as salt, to tightly-packed DNA in chromosomes, functional proteins, bio-membranes which enable the function of all life-on-earth, and even macroscopic structures such as bone, which shows a remarkable seven levels of hierarchical ordering) is that they display highly organized structures.
Interestingly, such materials are often generated by the self-assembly of smaller sub-units, where the composition and geometry of the sub-units dictates how they interact and then assemble. In this way, nature can construct complex materials with remarkable properties that go far beyond that achievable with small molecules.
Our research takes inspiration from these processes, and is investigating how assembly occurs over length scales ranging from the molecular to the mesoscale. Our researchers use state-of-the-art facilities to conduct impactful research across a variety of centres.
Addressing topics ranging from crystallisation, supramolecular assembly, nanoreactor templating, crystal engineering and the assembly of bio-molecules we are developing an understanding of the physico-chemical interactions which govern assembly processes.
With this insight, we are then able to design and build new structures/materials, with tailor-made properties, where targets can include new molecular devices, catalytic materials, drug therapies, electronic components, sensors, energy storage or batteries.
We have opportunities for prospective postgraduate researchers. Find out more.
View all members of our research group and publications.
If you are interested in collaborating with us or joining our research team, please get in touch with a relevent staff member.
NextResearch areas


We offer individual cycling clothing for cycling clubs, cycling teams, company sports groups and groups of cyclists. This means you can have high-quality and innovative cycling jerseys, cycling pants, cycling suits and accessories in our own design.
For each sports, whether cycling, triathlon, mountain biking or downhill, from cool bike jerseys to cycling jackets. All 100% individually printable also in small editions.
Nearly all articles are also available for kids. Our children sizes start at 116 and reach up to 164. The children articles are: Short sleeves jerseys, long sleeve jerseys, windbreaker bodies, winterjackets, rain jackets, sleeveless jerseys, bib shorts, long cycling bibs, arm warmers, leg warmers, cycling gloves, cycling caps ans headgear.
We offer custom cycling wear for clubs, teams and companies.
You can choose between different cuts and materials. Our article are in four categories, Classic, Performance, Ultimate and ProSeries. Classic Series is often used for event jersey, like Finisher Shirts. The Performance series stands for a very good clothing, with classic cuts. The Ultimate Series tops the Performance Series with more different fabrics, and plays with this high tech fabrics. The top of our range is the ProSeries, with modern, stylisch cuts, latest features and the neuste fabrics.
Short sleeves jerseys, long sleeve jerseys, windbreaker bodies, winterjackets, rain jackets, sleeveless jerseys, bib shorts, long cycling bibs, arm warmers, leg warmers, cycling gloves, cycling caps ans headgear.
The roots from RenéRosa are in cycling, because Tina-Rosa and René both came from cycling sports. So that is why cyclingwear is our main competence. René is still testing and developing the articles by himself to having the best prdoucts for the RenéRosa customers. It is not only his experience as procyclist, it is also his knowledge as engineer and his love for details and excellence. With our own production we can react very fast and develop new products and make changes for the customers demand.


The Hammered Aluminum Sunburst Earrings are made and finished by hand, making them truly exceptional in terms of their quality. Aluminum is nonreactive, so these earrings will never tarnish or turn color, and they are finished with durable 14K Gold-plated French Earwires. The earrings are 2 1/4 inches long by 1 1/2 inches wide.


text:
The Mauritanian Royal Family Mausoleum
By Mohammed Bokreta
Islamic Tourism: It is true to say that this historic masterpiece is one of the most interesting archaeological sites. It is believed that this large construction dates back to 100 BC. It is in surprisingly good condition, especially when compared to the younger Roman ruins in other parts of Algeria.
Only six kilometres away from Tipasa on a hilltop, 260m above sea level, overlooking the region, stands this impressive Mausoleum of the Royal Family of Mauritania. It is 32 meters high, 61 meters diameter and contains 80'000 cubic meter of stone blocks.
There are 60 columns running around the cylindrical structure. It has been constructed with four fake doors into the interior, while the real door was not discovered until 185, when it was discovered that it leads into a chamber, that proved to be empty.
It was built for King Juba II and his wife Cleopatra Selena, daughter of the famous Cleopatra of Egypt. Juba II who reigned from 25 BC to 23 AD over Mauritania which had its capital in Iol (presently Cherchell). Juba II was of Berber origin and the Kingdom of Mauritania covered what is now Morocco and Algeria.
The genuine monument's entrance, ignored for such a long time is situated in the bedrock or the basement of the wrong eastern door. It was discovered through the excavation campaign in 1865 led by Adrien Berbrugger, the historic monument's inspector who worked on the instructions of Napoléon III.
A similar 18.5 meter monument is to be found in eastern Algeria. It is called "the Medracen" near the city of Batna
It is believed that this large construction dates back to 100 BC. (19/12/2008)
Casablanca Office / Agents
Mr. Nour-eddine Saoudi
Mrs. Samera Bnalaede
163, rue Taha Hussein, Casablanca-Morroco
Mobile: +21 2 62 047 606
Tel/fax:+212 22 29 90 87
E-mail: itmcasablanca@tcph.org
����� ��� ����� �����
������ ����� �������
163 ���� �� ����
����� �������-������� ��������
������ ����� �������: �����ȡ ������ѡ ���ӡ ���������
Mauritania begins promoting desert and cultural tourism


Celebrate YOUth week 2019 with these FREE activities.
Bring your own inline or roller skates or borrow a pair from us. Enjoy disco lights, music and food.
3:30-6:30 pm. Call SOS to pre-register.
6:00-9:00 pm. Free admission. Prizes and free pizza.
3:00-5:30 pm. Parksville Family Place.


text:
New Summer 2015 #2
Peter S	Classroom Crisis, Durarara! x2, Gate	 July 7, 2015 August 11, 2015 6 Minutes
Ushio to Tora … not bad.
Ushio to Tora's first second is dark and mysterious, and leads to a an old story.
The grumpy son of a local priest is told to air out the storeroom, and he trips over a basement door, goes down, of course, and meets Tora, a demon who's been stuck there for 500 years because of the Beast Spear pinning him to the wall. Ushio isn't stupid, though he has moments (Tora being even more stupid about his motives gives him away), and he goes back upstairs, well, until youkai start swarming the place, attracted by Tora, and threatening two girl classmates, including the tsundere love interest Nakamura. So Tora gets released to help out and some mayhem ensues.
Not really my thing, but there's stuff to like here. Tora would gladly devour Ushio, but the kid's still got that spear, and Ushio needs Tora to drive the youkai away–at least for a while. Tora goes from nasty looking demon to cringing doggie, and Ushio goes from average boy to badass, grinning, long-haired warrior when the spear possesses him, and both are fun to watch. When they shout at each other it's even more fun; you can tell the seiyuus are having a good time. It's apparently an older work, so it looks dated, but there's nothing seriously wrong with the animation. It could be an entertaining watch, but, as I said, not my bag.
Your typical night time fade-in.
Next we have Gate, where Youji, your average otaku is on his way to an event in Tokyo when a gate looking like a roman building appears downtown and a whole mess of demons, fighting pigs, Roman legionaries, oh, and dragons, start pouring out and attacking people. Youji, who's been a goof until now, snaps into action and starts directing traffic and ordering police around, and I'm wondering where the hell he got the authority. But the show also slips in interesting bits, like two invaders wondering where the hell they are and if this was a good idea. Also, dragons turn out to be no match for military helicopters with machine guns, much less the forces on the ground, and the invasion is soon over. But the gate is still there …
Our otaku hero takes out a centurian.
This show could be dreadful or it might be all right. It starts dreadfully since we didn't know Youji was on the Special Defense Force, but once we learn that it gets more interesting. Japan regroups and now its their turn to go through the gate. Will they meet opposition? Well, yes. Will they meet some fairlyland people who aren't into all this invading? Possibly, judging from the elf-girls the show teases us with. But I don't really know what to expect, and that's a good thing.
An appropriate way to start Joukamachi no Dandelion.
Joukamachi no Dandelion has finally showed up. We start with a big, happy family waking up, having breakfast, fighting over the one bathroom, the usual, and then we learn that the father is king, and that his nine-odd offspring are all royalty. They live in a modest suburban home to give the kids a normal upbringing, though why they couldn't have one more bathroom is beyond me. What's more, the King has declared that his successor will be chosen by popular vote, and there's much to-do in the country with monthly rankings. AND, all the kids have their own super-power! Camera-shy Akane can fly, and when she does, people can look up her short school uniform skirt.
The royal family.
Yeah, it's an odd mix. Maybe the oddest thing of all is that they're going the happy domestic comedy route rather than murder and intrigue route with this whole successor business. Everyone seems well-adjusted apart from Akane, and she's just a little shy. They don't begrudge each other their popularity rankings and cheer each other on during a silly television game show they're forced to do. For that reason this series might turn out pretty dull. Right now the only thing that stands out is the weird setup. But it's a cute, happy show, so I might watch it for a while.
Here's another odd setup: Classroom Crisis.
Classroom Crisis starts with this … er, I can't read it.
With a title like that you expect a high school romcom series, and you'd be partly right, except this class is in the future, after more of the solar system has been terraformed. Still, they're excited about a transfer student. Meanwhile, the CEO of the corporation that runs the school's brother or son or something has been taken hostage way off on an asteroid mine and there's no way to get the money there fast enough. But the intrepid kids of class A-TEC, with their engineer homeroom teacher find a way, no, scratch that, the monotoned Iris takes an experimental rocket there, but there are complications …
In terms of science, I'm not expecting much from this show.
So it starts out as a hostage story, switches to romcom, then there's a mad spaceship dash, and the surprise at the end that the hostage probably wasn't worth rescuing. That's a lot for an episode to juggle, but it does it well, in spite of some silly science they toss in. The show thought through how hard it would be to pay a ransom to criminals with no bank accounts; details like that make me take notice that this show might not just goofing around (though that's fine too) and wants to give us a complex futuristic society, albeit with old-school looking spaceship capers. But it also ignores things for story–how did Iris get that ransom money to deliver in the first place? There's also the conflict it's setting up about putting people first vs a person's worth to a company. Some good points, some bad points. Could be interesting. Don't know if I want to spend a half hour a week watching Kiryu, or hear Sera's speeches, though Iris is a lot of fun.
A hot sunset.
Shimoneta to Iu Gainen ga Sonzai Shinai Taikutsu na Sekai (Shimoneta from here on out), set in a Japan where not only porn is banned (there goes the economy), but dirty words or even references to sex. Our hero, Tanukichi, enters the most moral high school of them all to get closer (platonically, he swears) to student president Anna. But he also runs into a indecent terrorist named Blue Snow, who tosses dirty cards to passers by and seems to be the only character in the show who's enjoying herself. And guess who the student VICE president is?
You go, Ayame!
This is the first show this season that made me laugh out loud. Repeatedly. And it wasn't the dirty jokes–most of them are bleeped out. They set up Ayame's transition from stern VP to laughing terrorist perfectly. Suddenly she's grinning, and you KNOW something isn't right. And once she's revealed she's great fun to watch, with her slightly crazed expression and her rich-girl laugh. Tanukichi starts as a dull male lead but turns out to have excellent straight-man timing. Then they throw in Hyoka, the science girl who's far too into learning how reproduction works (since the students are not told and so have some weird ideas), and it gets even better. The gags mostly work, the direction and timing are spot-on, and it leads to a terrorist event involving dirty cards, a video of flies mating and ridiculous imagery including Godzilla … Even if dirty jokes aren't your thing, you might enjoy this.
The new Durarara starts with Mikado, posing.
Finally for this installment it's Durarara! x2 Ten, where our favorite weirdos and lowlifes sort of meander around waiting for plot to happen. Izaya's recovering in the hospital, even so he tries to mess with people, setting up a fight with Shizuo, getting the police to call Shinra and ruining the man's date with Celty. Meanwhile, the spectre of his assailant, Jinnai, grows larger. He's got Yagiri industries listening to him, and we know Yagiri's up to no good. And Izaya is confronted by a new character who doesn't seem to be weird at all, only formerly suicidal.
Considering the series this is pretty good advice.
Basically the show is reintroducing everyone again, thought it wasn't that long since last season, having them think to themselves about this or that issue, and the incredible yesterday was. Masaomi wants to see Mikado and Anri again, that twin-tailed girl whose name I forget gets some screentime, everyone's waiting for the new story, or stories, and so are we.
Joukamachi no Dandelion
Shimoneta
Published July 7, 2015 August 11, 2015
Previous Post New Summer 2015 #1
Next Post New Summer 2015 #3


Niall Kirk of La Casa Tropical – Forgotten Palms.
Episode 140 of the Dream Chimney podcast features Niall Kirk of La Casa Tropical spinning, in his words, "afrobeat, vintage synth funk and lofi psych disco." A SoundCloud commenter also identifies K. Frimpong & His Cubano Fiestas.
Max Kane & Trailer Limon – Ego Death.
Tuxedo (Mayer Hawthorne x Jake One) – Number One.
Pepsi Max Presents Snoop Dogg, Mayer Hawthorne & Dam-Funk Live, March 19th, 2011.
Josh Hey - four gold chains.